Extreme Thrombocytosis in Refractory ITP Post-Splenectomy With Associated Fatal Thromboembolism

Thrombopoietin (TPO)-receptor agonists have heralded a paradigm shift in the treatment of refractory immune thrombocytopenia (ITP). Reactive thrombocytosis has been described as a secondary effect of such therapies. However, the phenomenon of extreme thrombocytosis with morphology mimicking a myelop...

Descripción completa

Detalles Bibliográficos
Autores principales: Nedumannil, Rithin, Leitinger, Emma, Juneja, Surender
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2022
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8905198/
https://www.ncbi.nlm.nih.gov/pubmed/35284824
http://dx.doi.org/10.1177/2632010X221083218
Descripción
Sumario:Thrombopoietin (TPO)-receptor agonists have heralded a paradigm shift in the treatment of refractory immune thrombocytopenia (ITP). Reactive thrombocytosis has been described as a secondary effect of such therapies. However, the phenomenon of extreme thrombocytosis with morphology mimicking a myeloproliferative neoplasm (MPN) followed by fatal thromboembolism is unusual in this setting. Caution is required in the diagnosis of refractory ITP as well as TPO-receptor agonist dosing in such cases.

Ejemplares similares